Hi,
While waiting for SANTA...
In my brief video review of my #4 of my top 10 CLL abstracts from ASCO 2019 I share the reassuring news that lowering or holding doses of duvelisib did not appear to lessen its efficacy in relapsed/refractory CLL.
The link is: cllsociety.org/2019/12/asco...
I also bring the good news from ASCO 2019 that 2/3 of the relapsed/refractory CLL patients who were intolerant of ibrutinib were doing well over a year and half out after switching to acalabrutinib. Watch my video review of my #3 pick
See: cllsociety.org/2019/12/acso...
Again I was interviewed by Demetri Kofinas in Manhattan for the internationally recognized podcast. It’s a long telling of my story, but I think you will enjoy it and maybe learn something new. Please give a listen here: hiddenforces.io/podcasts/br....
Finally, welcome back to the fourth and final 2019 Issue of The CLL Society Tribune! Lots of great articles by doctors and patients here: cllsociety.org/quarter-4-20...
That should be enough CLL reading and listening to keep you awake until long after Santa arrives. Or maybe you just want to sit by the fire and enjoy family and friends and forget CLL for a few days.
Merry Christmas. Happy Hanukkah.
Stay strong.
We are all in this together.
Brian
Brian Koffman MDCM (retired) MS Ed
Co-Founder, Executive VP and Chief Medical Officer
CLL Society, Inc